Barclays raised the firm’s price target on Celldex (CLDX) to $24 from $21 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex Therapeutics Advances Barzolvolimab Study for Chronic Urticaria
- Celldex Therapeutics Completes Promising Phase 2 Study on Chronic Inducible Urticaria Treatment
- These 3 Unknown Stocks Can Double, Say Five-Star Analysts – 12/11/2025
- Celldex’s Promising Market Opportunity: Buy Rating Backed by Phase III Trial and Revenue Projections
- Celldex’s Strategic Advancement in Phase 3 Trials for Barzolvolimab: A Promising Opportunity in Chronic Inducible Urticaria Treatment